+20 years of clinical validation.
200 research collaborations. 100s of publications

Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.


803, 2021

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Maganini, Cathy Graham, Beth-Ann Lesnikoski, Kathryn Wagner, June Lee, Julian Berrocal, Amy M. Truitt, Erin Yoder, Lisa Blumencranz, Bastiaan van der Baan, William Audeh, FLEX Investigators’ Group Background: Genomic expression profiles have implications for the personalized treatment of breast cancer Read More

2912, 2020

Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients

  PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Heather M. Kling, Sahra Uygun, Sarah Untch, William Audeh, Jennifer A. Crozier, Mehran Habibi, and Raquel Nunes Background: African American breast cancer (BC) patients (AA) are diagnosed at a younger age and present more frequently with triple-negative/Basal tumors than Caucasian Read More

2912, 2020

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

PUBLICATION: SABCS 2020 AUTHORS: Margaret Chen, Ava Kwong, Carolyn Hendricks, Nina D'Abreo, Laura Lee, Hatem H. Soliman, Charles Cox, Heather M. Kling, Midas M. Kuilman, Rajith Bhaskaran, Shiyu Wang, Andrea Menicucci, Sarah Untch, William Audeh, FLEX Investigators Group Background: Breast cancer incidence in Asian populations has increased in recent years Read More

2912, 2020

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Andrea Menicucci, Erin Yoder, Shiyu Wang, William Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. With goals of minimizing potential exposure to SARS-COV-2, as well as resource rationing, physicians are urged Read More

2912, 2020

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

  PUBLICATION: SABCS 2020AUTHORS:Peter W. Blumencranz, Mehran Habibi, Lisa Blumencranz, Andrea Menicucci, Shiyu Wang, Amy Truitt, William Audeh, Jolanta L. Baginski, Steven Shivers, Geza Acs, Charles E. Cox, MINT Investigators Group.Background:Elderly breast cancer (BC) patients are an understudied population, with limited evidence regarding treatment options and outcomes, and a lack of Read More

2912, 2020

Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification

PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Srkalovic, Patricia Robinson, Clodia Osipo, Kalyan Banda, Heather M. Kling, Midas M. Kuilman, Josien Haan, William Audeh, and FLEX Investigators Group Background: Invasive lobular carcinoma (ILC) comprises 10-15% of breast tumors and is the second most common histological type after Read More

2912, 2020

Differential gene expression and clinical utility of MammaPrint and BluePrint in male breast cancer patients

PUBLICATION: SABCS 2020 AUTHORS: Jennifer A. Crozier, Julie Barone, Kalyan Banda, Beth Lesnikoski, Robert Maganini, Sami Diab, Ian Grady, Thomas Lomis, Charles Cox, Amy M. Truitt, Benjamin Nota, Andrea Menicucci9, Midas Kuilman, Erin Yoder, William Audeh, FLEX Investigators Background: Male breast cancer (MaBC) is rare, comprising <1% of all breast Read More